Leadership Team

Brent Zettl, President and CEO

Mr. Zettl, BScA Distinction (Agriculture), is a pioneer of the Canadian medical cannabis industry. He co-founded Prairie Plant Systems Inc. and CanniMed Therapeutics Inc. in 1988. CanniMed was the exclusive supplier of medical cannabis to Health Canada from 2000 to 2014. In March 2018, CanniMed was acquired by Aurora Cannabis Inc. for ~CAD$1.2 billion, the largest acquisition of a cannabis company at the time.

Keith Carpenter, Chief Strategy and Investment Officer

Mr. Carpenter, BA (Economics), MBA, CFA, has more than 20 years of investment experience, spanning both the buy and sell-side. He has spent the last ten in agriculture equity research, where he was a Brendan Wood Top Gun-ranked analyst and StarMine Award recipient.

Rob Harding , Chief Financial Officer

Mr. Harding, MBA, CPA, CMA, has more than 20 years of experience building dynamic, high-performing finance teams and successfully leading companies through public and private financing. He was the CFO at Athabasca Oil, achieving a peak market valuation of $7 billion. His most recent position was CFO of Radicle, where he was involved in the development of Canada’s largest independent green fund.

Dr. Lionel Marks de Chabris, Chief Medical Officer

As a leading expert in chronic pain management and addictions medicine, Dr. Marks de Chabris brings 30 years of medical expertise to ZYUS where he is Chief Medical Officer, chairman of ZYUS’ Clinical Advisory Committee and spearheads the company’s Healthcare Practitioner Education Program. Prior to joining ZYUS, Dr. Marks de Chabris established one of only three Chronic Pain Management centers in northern Ontario. He continues to serve as an assistant professor at the Northern Ontario School of Medicine. Dr. Marks de Chabris’ pain management practice is recognized by the Ontario Medical Association and he has been accepted by the Ontario Superior Court as an expert in pain medicine and addiction medicine. In addition, he is a diplomate of the Canadian Academy of Pain Management and the American Board of Addiction Medicine, and he is acknowledged as a Fellow of the College of Family Physicians of Canada with expertise in addiction medicine.

Larry Holbrook, Chief Scientific Officer

Dr. Holbrook, PhD (Neurobiology), has been a senior research scientist in a number of Canadian biotechnology R&D companies for more than 35 years. His main research focus has been the utilization of molecular biology to develop plant made pharmaceuticals, including cannabinoids. He most recently held the position as Chief Scientific Officer at CanniMed.